Ali Behbahani
InvestorGeneral Partner at New Enterprise Associates (NEA) · Board director at Nexo Therapeutics, Inc. · Board director at Launchpad Therapeutics, Inc. · Board director at FirstLight Bio, Inc.
Menlo Park, CA
Writes $2M – $50M checks · typically $25M
About
Ali Behbahani, M.D., is a healthcare investor at NEA focused on the biopharmaceutical and medical device sectors. He joined NEA in 2007 and became a partner in 2013 before being promoted to General Partner in 2018. Earlier in his career he worked as a Venture Associate at Morgan Stanley Venture Partners, in business development at The Medicines Company, and as a healthcare investment banking analyst at Lehman Brothers. He holds an MD from the University of Pennsylvania School of Medicine and an MBA from the Wharton School.
Contact· self-published, not guessed
Invests in
BiotechDigital HealthMedical Devices
Board director at Nexo Therapeutics, Inc.
Intro paths
In turn, Ali can intro founders to Nexo Therapeutics, Inc.'s investors below.
Nexo Therapeutics, Inc.'s investors · 2
Board director at Launchpad Therapeutics, Inc.
Intro paths
In turn, Ali can intro founders to Launchpad Therapeutics, Inc.'s investors below.
Launchpad Therapeutics, Inc.'s investors · 2
Board director at FirstLight Bio, Inc.
Intro paths
In turn, Ali can intro founders to FirstLight Bio, Inc.'s investors below.
FirstLight Bio, Inc.'s investors · 1
Experience
- New Enterprise AssociatesPartnercurrent2007 — presentChevy Chase, MD
- The Medicines CompanyConsultant2003 — 2005Parsippany, NJ
- The Medicines CompanySummer Business Development Associate2003Parsippany, NJ
- Morgan Stanley Venture PartnersVenture Associate2000 — 2002
- Lehman BrothersAnalyst1998 — 2000
Skills & more
From Ali's professional profile.
Deals · 19
Nexo Therapeutics, Inc.Board seat
via New Enterprise Associates (NEA) · filed Mar 2026 · $60M raise
Spyglass PharmaBoard seat
via New Enterprise Associates (NEA) · filed Jun 2025 · $75M raise
Tune TherapeuticsBoard seat
via New Enterprise Associates (NEA) · filed Jan 2025 · $208M raise
858 Therapeutics, Inc.Board seat
via New Enterprise Associates (NEA) · filed Jul 2024 · $50.4M raise
Launchpad Therapeutics, Inc.Board seat
via New Enterprise Associates (NEA) · filed Dec 2022 · $30M raise
FirstLight Bio, Inc.Board seat
via New Enterprise Associates (NEA) · filed Apr 2022 · $25.4M raise
Monte Rosa TherapeuticsBoard seat
via New Enterprise Associates (NEA) · filed Sep 2020 · $96M raise
Genocea BiosciencesBoard seat
via New Enterprise Associates (NEA) · filed Aug 2020 · $79.9M raise
CRISPR Therapeutics AGBoard seat
via New Enterprise Associates (NEA) · filed Apr 2020 · $1M raise
ArcellxBoard seat
via New Enterprise Associates (NEA) · filed Oct 2019 · $83.7M raise
Nkarta, Inc.Board seat
via New Enterprise Associates (NEA) · filed Sep 2019 · $114.6M raise
Aset TherapeuticsBoard seat
via New Enterprise Associates (NEA) · filed Jul 2019 · $87.2M raise
CVRxBoard seat
via New Enterprise Associates (NEA) · filed May 2019 · $93M raise
Minerva SurgicalBoard seat
via New Enterprise Associates (NEA) · filed Mar 2018 · $20M raise
Oyster Point Pharma, Inc.Board seat
via New Enterprise Associates (NEA) · filed Oct 2017 · $43.1M raise
Ivantis IncBoard seat
via New Enterprise Associates (NEA) · filed Jan 2017 · $25M raise
Solace TherapeuticsBoard seat
via New Enterprise Associates (NEA) · filed Sep 2016 · $20M raise
Rotation MedicalBoard seat
via New Enterprise Associates (NEA) · filed Aug 2016 · $8M raise
CardionomicBoard seat
via New Enterprise Associates (NEA) · filed Oct 2015 · $21.8M raise
Attribution from SEC filings, press coverage, and firm rosters.
Other disclosed investments
Led
AdaptimmuneCRISPR TherapeuticsNkarta
Board seats
GenoceaIvantisNevroNkartaOyster Point Pharma
Sources: the firm's website · SEC Form D filings.
Colleagues at New Enterprise Associates (NEA)
Network15
▶3 more connections
Investors connected to Ali in public investor directories — a warm-intro map.
Frequently asked questions
- Who is Ali Behbahani?
- Ali Behbahani, M.D., is a healthcare investor at NEA focused on the biopharmaceutical and medical device sectors. He joined NEA in 2007 and became a partner in 2013 before being promoted to General Partner in 2018. Earlier in his career he worked as a Venture Associate at Morgan Stanley Venture Partners, in business development at The Medicines Company, and as a healthcare investment banking analyst at Lehman Brothers. He holds an MD from the University of Pennsylvania School of Medicine and an MBA from the Wharton School.
- Where does Ali Behbahani work?
- Ali Behbahani is General Partner at New Enterprise Associates (NEA) and Board director at Nexo Therapeutics, Inc. and Board director at Launchpad Therapeutics, Inc. and Board director at FirstLight Bio, Inc..
- What does Ali Behbahani invest in?
- Ali Behbahani invests in Biotech, Digital Health, Medical Devices.
- What check size does Ali Behbahani write?
- Ali Behbahani typically writes checks of $2M – $50M.
- What boards does Ali Behbahani sit on?
- Ali Behbahani holds tracked board seats at 858 Therapeutics, Inc., Arcellx, Arcellx, Aset Therapeutics, Cardionomic, Cardionomic, CRISPR Therapeutics AG, CVRx, CVRx, FirstLight Bio, Inc..
- What companies has Ali Behbahani invested in?
- Investments tracked here include Adaptimmune, Arcellx, CRISPR Therapeutics, Nkarta.
- Where did Ali Behbahani go to school?
- Ali Behbahani studied at The Wharton School (MBA, Healthcare Management); University of Pennsylvania (MD, Medicine); Duke University (BSE, BME).
- Does Ali Behbahani lead rounds?
- Yes — Ali Behbahani has led 4 tracked investments.
Same school
Also attended The Wharton School1,557
+ 1,551 more
Also attended University of Pennsylvania824
+ 818 more
Also attended Duke University522
+ 516 more
Shared employers
Also worked at The Medicines Company4
Also worked at Morgan Stanley Venture Partners1,001
+ 995 more
Also worked at Lehman Brothers253
+ 247 more